EUCTR2013-004860-78-GB进行中（未招募）不适用
A randomised, active-controlled, observer-blind, non-inferiority study to investigate the efficacy, safety and tolerability of a local treatment with dimeticone-based pediculicides in head lice infestation. - NEX in head lice infestation. Version 1.0
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 194
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Healthy subjects without confounding disease and/or medication with head lice;
- •2. Male and female subject ages 2 to 11 years (inclusive);
- •3. Outpatients;
- •4. Presence of at least 3 viable head lice after visual inspection of the scalp;
- •5. The physical examination of the scalp must be without abnormal findings (except the symptoms due to head lice infestation) unless the investigator considers an abnormality to be irrelevant to the outcome of the clinical investigation;
- •6. For subjects aged 8-11 years: subjects willing and able to sign written informed assent and written informed consent obtained from their parent(s)/legal guardian(s). For subjects under 8 years: written informed consent obtained from their parent(s)/legal guardians.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 194
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Treatment with other head lice products within two weeks before and during the clinical investigation;
- •2. Treatment with antibiotics (e.g. cotrimoxazole, trimethoprim or tetracycline) within four weeks before and during the clinical investigation;
- •3. Treatment with anthelminthic drugs (e.g. ivermectin, levamisole or albendazole) within four weeks before and during the clinical investigation;
- •4. Severe skin disorder of the scalp (e.g. generalized impetigo, eczema, psoriasis or chronic dermatitis of unknown origin);
- •5. Usage of lice combs during the clinical investigation by the participants themselves or by the parent(s)/legal guardian(s);
- •6. Use of shampoos containing dimeticone during the investigation;(a dimeticone -free shampoo such as Johnson’s Baby Shampoo will be provided for all participants by the sponsor);
- •7. Use of hair bleaches, dyes, or permanent wave products during the investigation;
- •8. Symptoms of a clinically significant illness that may influence the outcome of the investigation in the four weeks before and during the clinical investigation;
- •9. Participation in the treatment phase of another clinical investigation or trial within the last four weeks prior to the first administration of IMD / IMP in this clinical investigation and during the clinical investigation;
- •10. Enrolment of a family member in the clinical investigation;
- •11. Known hypersensitivity or allergic reactions to components of the IMD / IMP;
- •12. Hair condition/texture prevents 100 ml IMD/IMP to be sufficient for one application in the opinion of the study nurse. Special attention should be paid to subjects whose hair length falls below mid-back
- •13. Contraindications according to the instructions for use and information given in the IB;
- •14. If in the opinion of the investigator or the clinical research nurse performing the initial examination the subject should not participate in the clinical investigation, e.g. due to probable noncompliance or inability of the subject or parent(s)/legal guardian(s) to understand the investigation and give adequately informed consent/assent;
- •15. Close affiliation with the investigator (e.g. a close relative) or persons working at LSHTM or the subject or subject’s parent(s)/legal guardian(s) is an employee of the sponsor;
- •16. Subject is institutionalized because of legal or regulatory order.
研究者
相似试验
进行中（未招募）
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001082-17-ATMENARINI RICERCHE S.p.A.600
进行中（未招募）
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001082-17-HUMENARINI RICERCHE S.p.A.600
进行中（未招募）
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001082-17-CZMENARINI RICERCHE S.p.A.600
进行中（未招募）
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001082-17-HRMENARINI RICERCHE S.p.A.600
进行中（未招募）
1 期
Study to compare Delafloxacin intravenous and oral single drug therapy with best available treatments in patients with surgical site infectionsAcute Bacterial Skin and Skin Structure InfectionMedDRA version: 20.1Level: PTClassification code 10052891Term: Skin bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001082-17-GBMENARINI RICERCHE S.p.A.600